Publications by authors named "Thomas Cosgriff"

Claim this Profile
E
Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer.
Fred R Hirsch, Ramaswamy Govindan, Zanete Zvirbule, Fadi Braiteh, Achim Rittmeyer, Thomas Cosgriff

Clin Lung Cancer· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
Heather Wakelee, Zanete Zvirbule, Filippo De Braud, C Daniel Kingsley, Tarek Mekhail, Thomas Cosgriff

Clin Lung Cancer· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.
Robert J Motzer, Carlos H Barrios, Tae Min Kim, Silvia Falcon, Thomas Cosgriff

J Clin Oncol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
Barry Mirtsching, Thomas Cosgriff, Graydon Harker, Mark Keaton, Tarek Chidiac

Clin Breast Cancer· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
Ralph V Boccia, Thomas M Cosgriff, David L Headley, Suprith Badarinath, Shaker R Dakhil

Clin Colorectal Cancer· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
Roger M Lyons, Thomas M Cosgriff, Sanjiv S Modi, Robert H Gersh, John D Hainsworth

J Clin Oncol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea.
Janice M Rusnak, William R Byrne, Kyung N Chung, Paul H Gibbs, Theodore T Kim, Thomas Cosgriff

Antiviral Res· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Roger B Cohen, Corey J Langer, George Rajan Simon, Peter David Eisenberg, John Daniel Hainsworth, Thomas Michael Cosgriff

Cancer Chemother Pharmacol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis